CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysisIn VitroCBR-470-2 (1-10 μM; 24 h) increases transcript levels of the NRF2-responsive genes NQO1 and HMOX1 in epidermal keratinocytes and dermal fibroblasts. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoCBR-470-2 (50 mg/kg; p.o. twice daily for 10 d) induces activation of NRF2 signaling in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/C mice (5-week old) are exposed to UVB Dosage: 50 mg/kg Administration: P.o. twice daily for 10 days Result: Resulted in comparable beneficial effects on erythema histological scores and total wounded area. Decreased epidermal thickness in response to UV exposure.Form:SolidIC50& Target:NRF2. Specification: 0.99 Molecular Formula: C12H13Cl2NO6S2 Molecular Weight: 402.27 PubChem CID: 155819525
- UPC:
- 41181887
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- C650324-10mg
- CAS:
- 2416095-00-4
- Product Size:
- 10mg
